412 related articles for article (PubMed ID: 32563550)
1. Plasma from donors convalescent from SARS-CoV-2 infection-A matter of priorities.
Farrugia A
Transfus Clin Biol; 2020 Aug; 27(3):167-168. PubMed ID: 32563550
[No Abstract] [Full Text] [Related]
2. Use of convalescent plasma in COVID-19 patients in China.
Zhu M; Hu K; Zhu Z
Transfus Clin Biol; 2020 Aug; 27(3):168-169. PubMed ID: 32425645
[No Abstract] [Full Text] [Related]
3. The convalescent sera option for containing COVID-19.
Casadevall A; Pirofski LA
J Clin Invest; 2020 Apr; 130(4):1545-1548. PubMed ID: 32167489
[No Abstract] [Full Text] [Related]
4. Convalescent plasma, an apheresis research project targeting and motivating the fully recovered COVID 19 patients: A rousing message of clinical benefit to both donors and recipients alike.
Seghatchian J; Lanza F
Transfus Apher Sci; 2020 Jun; 59(3):102794. PubMed ID: 32448638
[No Abstract] [Full Text] [Related]
5. Feasibility of a pilot program for COVID-19 convalescent plasma collection in Wuhan, China.
Li L; Yang R; Wang J; Lv Q; Ren M; Zhao L; Chen H; Xu H; Xie S; Xie J; Lin H; Li W; Fang P; Gong L; Wang L; Wu Y; Liu Z
Transfusion; 2020 Aug; 60(8):1773-1777. PubMed ID: 32491199
[TBL] [Abstract][Full Text] [Related]
6. Characteristics and serological patterns of COVID-19 convalescent plasma donors: optimal donors and timing of donation.
Li L; Tong X; Chen H; He R; Lv Q; Yang R; Zhao L; Wang J; Xu H; Liu C; Chen G; Chen S; Li C; Qiao J; Yang J; Wu Y; Liu Z
Transfusion; 2020 Aug; 60(8):1765-1772. PubMed ID: 32627216
[TBL] [Abstract][Full Text] [Related]
7. Anti-SARS-CoV-2 virus antibody levels in convalescent plasma of six donors who have recovered from COVID-19.
Zhang L; Pang R; Xue X; Bao J; Ye S; Dai Y; Zheng Y; Fu Q; Hu Z; Yi Y
Aging (Albany NY); 2020 Apr; 12(8):6536-6542. PubMed ID: 32320384
[TBL] [Abstract][Full Text] [Related]
8. Convalescent Plasma and COVID-19.
Malani AN; Sherbeck JP; Malani PN
JAMA; 2020 Aug; 324(5):524. PubMed ID: 32530454
[No Abstract] [Full Text] [Related]
9. Position paper on the preparation of immune plasma to be used in the treatment of patients with COVID-19.
Accorsi P; Berti P; de Angelis V; De Silvestro G; Mascaretti L; Ostuni A;
Transfus Apher Sci; 2020 Aug; 59(4):102817. PubMed ID: 32532691
[TBL] [Abstract][Full Text] [Related]
10. Challenges in the Production of Convalescent Hyperimmune Plasma in the Age of COVID-19.
Franchini M; Del Fante C; Klersy C; Glingani C; Percivalle E; Baldanti F; Perotti C
Semin Thromb Hemost; 2020 Oct; 46(7):804-806. PubMed ID: 32512588
[No Abstract] [Full Text] [Related]
11. Convalescent plasma for COVID-19: male gender, older age and hospitalisation associated with high neutralising antibody levels, England, 22 April to 12 May 2020.
Mehew J; Johnson R; Roberts D; Harvala H
Euro Surveill; 2020 Nov; 25(45):. PubMed ID: 33183404
[TBL] [Abstract][Full Text] [Related]
12. COVID-19 convalescent plasma: phase 2.
Knudson CM; Jackson JB
Transfusion; 2020 Jun; 60(6):1332-1333. PubMed ID: 32374890
[TBL] [Abstract][Full Text] [Related]
13. Convalescent plasma treatment for SARS-CoV-2 infection: analysis of the first 436 donors in England, 22 April to 12 May 2020.
Harvala H; Mehew J; Robb ML; Ijaz S; Dicks S; Patel M; Watkins N; Simmonds P; Brooks T; Johnson R; Gopal R; Roberts DJ; Zambon M;
Euro Surveill; 2020 Jul; 25(28):. PubMed ID: 32700670
[TBL] [Abstract][Full Text] [Related]
14. Treatment for emerging viruses: Convalescent plasma and COVID-19.
Brown BL; McCullough J
Transfus Apher Sci; 2020 Jun; 59(3):102790. PubMed ID: 32345485
[TBL] [Abstract][Full Text] [Related]
15. Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma.
Shen C; Wang Z; Zhao F; Yang Y; Li J; Yuan J; Wang F; Li D; Yang M; Xing L; Wei J; Xiao H; Yang Y; Qu J; Qing L; Chen L; Xu Z; Peng L; Li Y; Zheng H; Chen F; Huang K; Jiang Y; Liu D; Zhang Z; Liu Y; Liu L
JAMA; 2020 Apr; 323(16):1582-1589. PubMed ID: 32219428
[TBL] [Abstract][Full Text] [Related]
16. A Randomized Open label Phase-II Clinical Trial with or without Infusion of Plasma from Subjects after Convalescence of SARS-CoV-2 Infection in High-Risk Patients with Confirmed Severe SARS-CoV-2 Disease (RECOVER): A structured summary of a study protocol for a randomised controlled trial.
Janssen M; Schäkel U; Djuka Fokou C; Krisam J; Stermann J; Kriegsmann K; Haberbosch I; Novotny JP; Weber S; Vehreschild M; Bornhäuser M; Bullinger L; Schmitt M; Liebregts T; Dreger P; Lorenz HM; Plaszczyca A; Bartenschlager R; Müller B; Kräusslich HG; Halama N; Jäger D; Schlenk RF; Leo A; Meuer S; Weigand MA; Motsch J; Merle U; Denkinger CM; Müller-Tidow C
Trials; 2020 Oct; 21(1):828. PubMed ID: 33023671
[TBL] [Abstract][Full Text] [Related]
17. Convalescent plasma therapy for B-cell-depleted patients with protracted COVID-19.
Hueso T; Pouderoux C; Péré H; Beaumont AL; Raillon LA; Ader F; Chatenoud L; Eshagh D; Szwebel TA; Martinot M; Camou F; Crickx E; Michel M; Mahevas M; Boutboul D; Azoulay E; Joseph A; Hermine O; Rouzaud C; Faguer S; Petua P; Pommeret F; Clerc S; Planquette B; Merabet F; London J; Zeller V; Ghez D; Veyer D; Ouedrani A; Gallian P; Pacanowski J; Mékinian A; Garnier M; Pirenne F; Tiberghien P; Lacombe K
Blood; 2020 Nov; 136(20):2290-2295. PubMed ID: 32959052
[TBL] [Abstract][Full Text] [Related]
18. Convalescent Plasma Therapy in Patients With Severe or Life-Threatening COVID-19: A Metadata Analysis.
Rabelo-da-Ponte FD; Silvello D; Scherer JN; Ayala AR; Klamt F
J Infect Dis; 2020 Oct; 222(9):1575-1578. PubMed ID: 32777038
[No Abstract] [Full Text] [Related]
19. Deployment of convalescent plasma for the prevention and treatment of COVID-19.
Bloch EM; Shoham S; Casadevall A; Sachais BS; Shaz B; Winters JL; van Buskirk C; Grossman BJ; Joyner M; Henderson JP; Pekosz A; Lau B; Wesolowski A; Katz L; Shan H; Auwaerter PG; Thomas D; Sullivan DJ; Paneth N; Gehrie E; Spitalnik S; Hod EA; Pollack L; Nicholson WT; Pirofski LA; Bailey JA; Tobian AA
J Clin Invest; 2020 Jun; 130(6):2757-2765. PubMed ID: 32254064
[TBL] [Abstract][Full Text] [Related]
20. Recruitment Strategy for Potential COVID-19 Convalescent Plasma Donors.
Andersen KJ; Klassen SA; Larson KF; Ripoll JG; Senefeld JW; Clayburn AJ; Shepherd JRA; Tseng AS; Wiggins CC; Murphy BM; Ford SK; Johnson CP; Miller AD; Baker SE; Wright RS; Winters JL; Stubbs JR; Joyner MJ; van Buskirk CM
Mayo Clin Proc; 2020 Nov; 95(11):2343-2349. PubMed ID: 33153626
[No Abstract] [Full Text] [Related]
[Next] [New Search]
